25 September 2024: Articles
Complex Interplay of COVID-19 ARDS with Guillain-Barré Syndrome and Cerebral Infarction: A Case Study
Unusual clinical course, Challenging differential diagnosis
Daiki Morikawa1A, Shigeki Fujitani1AE*, Tomoyuki Shirahige 1A, Yuta Hagiwara2A, Kenichiro Morisawa1A, Toru Yoshida1ADOI: 10.12659/AJCR.944390
Am J Case Rep 2024; 25:e944390
Abstract
BACKGROUND: Coronavirus disease (COVID-19) can cause various complications. We report a case of severe COVID-19 acute respiratory distress syndrome (ARDS) in a patient receiving veno-venous extracorporeal membrane oxygenation (V-V ECMO), complicated by Guillain-Barré syndrome (GBS) and cerebral infarction, as well as pulmonary embolism.
CASE REPORT: A 55-year-old Japanese man with a history of ulcerative colitis was admitted for COVID-19. His respiratory status worsened and progressed to ARDS, requiring intubation on hospital day (HD) 3. On HD 16, contrast computed tomography revealed PE. On HD 18, his respiratory condition worsened, and V-V ECMO was initiated. On HD 23, V-V ECMO was successfully discontinued. He regained consciousness on HD 44, but he had quadriplegia. Deep-tendon reflexes were absent in all limbs. Cranial nerve involvement, specifically bilateral facial nerve weakness, was noted. Magnetic resonance imaging showed bilateral scattered cerebral infarctions on HD 76. Nerve conduction studies indicated severe axonal neuropathy. Cerebrospinal fluid examination showed albuminocytologic dissociation. The antibody to the ganglioside GD1a was positive. These findings were consistent with the diagnosis of GBS. He received immunoglobulin treatment on HD 89, and his neurological findings slightly improved.
CONCLUSIONS: This study emphasized that in COVID-19, neurological complications are not rare, are difficult to diagnose, and are prone to delays in detection.
Keywords: cerebral infarction, COVID-19, Extracorporeal Membrane Oxygenation, Pulmonary Embolism, Respiratory Distress Syndrome, Guillain-Barré syndrome
Introduction
Coronavirus disease (COVID-19) can cause various complications. Neurological manifestations of COVID-19 have been reported in up to 36.4% of cases [1]. COVID-19 has been reported to be associated with various neurological symptoms, including dizziness, headache, confusion, myalgia, ageusia, and anosmia [1]. Several neurologic illnesses, such as encephalitis/encephalopathy, meningitis, and stroke, have reportedly occurred along with COVID-19 [1]. We report a case of severe COVID-19 acute respiratory distress syndrome (ARDS) complicated by neurological manifestations, including Guillain-Barré syndrome (GBS) and cerebral infarction, as well as pulmonary embolism (PE).
Case Report
A 55-year-old Japanese man with a history of ulcerative colitis (UC), hyperlipidemia, and hypertension was admitted to our hospital with dyspnea after 11 days of fever. He tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA on reverse transcriptase polymerase chain reaction (RT-PCR) and was diagnosed with COVID-19. The patient’s C-reactive protein level was 14.14 mg/dL. He was treated with ciclesonide, favipiravir, and methylprednisolone for COVID-19. His respiratory status worsened, and he developed ARDS, requiring intubation on hospital day (HD) 3. He received midazolam, propofol, and fentanyl for analog-sedation. On HD 8, he was able to grip with his hands and elevate his arms. Then, his respiratory condition worsened significantly. On HD 12, he developed a right pneumothorax, and a chest drain was inserted. He experienced anaphylactic shock, presumably due to xylocaine, during the insertion of a chest drain. Despite the insertion of a chest drain, oxygenation deteriorated. Therefore, a muscle relaxant, rocuronium, was added to his regimen to reduce breathing effort. Simultaneously, the dosage of propofol was increased, and on HD 14, his level of consciousness was GCS 1T1. On HD 16, contrast computed tomography revealed PE, and by HD 18, there was an added deterioration in respiratory status, presumably due to this PE, necessitating the initiation of veno-venous extracorporeal membrane oxygenation (V-V ECMO) in conjunction with ARDS. Rocuronium was temporarily resumed during the procedure. On HD 20, he exhibited progression of metabolic acidosis, and continuous hemodiafiltration (CHDF) was initiated. His respiratory status subsequently improved, and on HD 22, tracheostomy was performed. On HD 23, V-V ECMO was successfully discontinued. The doses of sedative agents were gradually decreased, and sedatives were then discontinued on HD 24 (Figure 1). On HD 44, he was able to follow commands with visual pursuit and nodding but was unable to move his extremities. The patient regained consciousness and was able to communicate by sticking out his tongue. He was noted to be completely quadriplegic. Magnetic resonance imaging (MRI) showed bilateral scattered cerebral infarctions (small high-intensity areas in the left and right precentral gyri, right superior frontal gyrus, and right occipital lobe) on HD 76 (Figure 2). We confirmed the absence of intracardiac thrombi on echocardiography and conducted a bubble study, which also confirmed the absence of a patent foramen ovale. The heparin therapy for PE, which had been discontinued on HD 64 due to anemia, was resumed. However, this did not explain the patient’s quadriplegia. Neurological examination revealed amyotrophy of all limbs, total paralysis of the extremities and the bulbar and facial muscles, and external ophthalmoplegia. Deep-tendon reflexes were absent in all limbs. Babinski reflex was absent. These findings were symmetrical. Cranial nerve involvement, specifically bilateral facial nerve weakness, was noted. A nerve conduction study showed delayed peripheral nerve conduction velocity, disappearance of the F wave, and decreased amplitude in the left median nerve. These findings were indicative of severe axonal neuropathy. Cerebrospinal fluid showed albuminocytologic dissociation, no white blood cells (0/mm3), and elevated protein levels (124 mg/dL). Blood serum testing showed strong positivity for IgG antibodies to the ganglioside GD1a. Antibodies to the gangliosides GQ1b and GM1 were not detected. These findings were consistent with the diagnosis of GBS. He received intravenous immunoglobulin (IVIG) (0.4 g/kg) for 5 days, starting on HD 89. His neurological symptoms slightly improved after therapy, and he was able to move both shoulders and his right hand (manual muscle testing, 2/5). On HD 95, the patient developed interstitial nephritis, presumably due to mesalazine.
Discussion
In this case, it was difficult to determine the onset of GBS because the neurological findings were difficult to evaluate in an isolated intensive care setting. Early detection of neurological complications is imperative to providing immediate intervention and achieving a better prognosis, but it is difficult to detect the initial symptoms of COVID-19-associated GBS. The initial symptoms included flaccid paralysis and facial diplegia, occurring 5–10 days after the onset of acute respiratory symptoms [2]. The initial symptoms of neurological complications in severe COVID-19 are challenging to diagnose because the patients are isolated, making neurological evaluation difficult, especially for intubated patients.
It was also difficult to diagnose the neurological complications of COVID-19, including GBS and stroke, because MRI and neurophysiological tests, including electroencephalography and nerve conduction studies, are difficult to perform in an intensive care setting. Moreover, safe nursing and adequate infection control need to be practiced.
Furthermore, it was difficult to differentiate GBS from other neurological diseases. Our patient was receiving V-V ECMO and was sedated with several drugs, including a muscle relaxant. General weakness was challenging to differentiate from ICU-acquired weakness (ICU-AW) and other neurological diseases. Muscle injury and myalgia are commonly reported neurological findings in COVID-19 (19.2%, 95% CI 15.4–23.2%) [3]. The weakness attributed to cerebral infarction on MRI was considered in the differential diagnosis. However, both pyramidal signs, including absent tendon reflexes and absent Babinski reflex, were noted, leading us to suspect a peripheral rather than central origin. Critical illness polyneuropathy (CIP) was one of the essential differential diagnoses in this patient. However, in CIP, peripheral facial paralysis is uncommon, and antiganglioside antibodies are not detected [4]. To differentiate GBS from other neurological diseases, antiganglioside antibody testing was useful in confirming the diagnosis of GBS, especially for an isolated intensive care setting because antiganglioside antibodies can be collected without moving, and are strongly associated with certain forms of GBS [5].
In our case, COVID-19 was complicated by GBS, cerebral infarction, and PE. These complications can be associated with cytokines. SARS-CoV-2 can induce an excessive immune reaction with increases production of cytokines, such as IL-6, by activated leukocytes. These stimulate the inflammatory cascade, leading to extensive tissue damage [6]. In this case, the patient developed respiratory failure, requiring V-V ECMO. In this state, a hyperinflammatory cytokine profile, often termed a “cytokine storm,” can be fatal. Cytokine storm is one of the clinical complications of SARS-CoV-2 infection [6]. In patients with GBS with mechanical ventilation, our patient required V-V ECMO (Table 1) [7–17]. In this case, the patient`s respiratory condition deteriorated to the point that V-V ECMO was required due to pulmonary embolism complicating ARDS caused by COVID-19. It is conceivable that this PE, similar to GBS and cerebral infarction, could have originated from a cytokine storm induced by COVID-19.
Cytokine storm was also associated with increased IL-6 levels, resulting in hyperviscosity and increased risk of stroke [6]. Hypercoagulability was also a possible cause of PE. In our case, the patient had COVID-19 complicated by stroke and PE. This case emphasized that multiple coagulation complications can occur sequentially in COVID-19.
Conclusions
Neurological complications of severe COVID-19 ARDS are challenging to diagnose because patients are deeply sedated, and neurological symptoms need to be distinguished from ICU-AW. Neurologic examinations in COVID-19 patients are also limited by isolation guidelines. Early detection and treatment of neurological complications are essential to achieve a good prognosis. This case emphasizes that neurological complications are not uncommon and are prone to delays in detection. When evaluating patients with COVID-19, neurological complications, including GBS and stroke, should be strongly suspected.
Figures
Figure 1.. Clinical course of case related to treatment. MV – mechanical ventilation; GCS – Glasgow Coma Scale; PE – pulmonary embolism; V-V ECMO – veno-venous extracorporeal membrane oxygenation; IVIG – intravenous immunoglobulin. Figure 2.. MRI with diffusion-weighted imaging (DWI) showed bilateral scattered cerebral infarction. A small high-intensity area was found on bilateral precentral gyrus, right superior frontal gyrus, and right occipital lobe. The areas indicated by the yellow arrows are small high-intensity areas.References:
1.. Mao L, Jin H, Wang M, Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China: JAMA Neurology, 2020; 77(6); 683-90
2.. Toscano G, Palmerini F, Ravaglia S, Guillain-Barré syndrome associated with SARS-CoV-2: N Engl J Med, 2020; 382(26); 2574-76
3.. Pinzon RT, Wijaya VO, Buana RB, Neurologic characteristics in coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis: Front Neurol, 2020; 11; 565
4.. Zhou C, Wu L, Ni F, Critical illness polyneuropathy and myopathy: A systematic review: Neural Regen Res, 2014; 9(1); 101-10
5.. Gregson NA, Koblar S, Hughes RA, Antibodies to gangliosides in Guillain-Barré syndrome: Specificity and relationship to clinical features: Q J Med, 1993; 86(2); 111-17
6.. Chen G, Wu D, Guo W, Clinical and immunological features of severe and moderate coronavirus disease 2019: J Clin Invest, 2020; 130(5); 2620-29
7.. De Sanctis P, Doneddu PE, Viganò L, Guillain-Barré syndrome associated with SARS-CoV-2 infection. A systematic review: Eur J Neurol, 2020; 27(11); 2361-70
8.. Wada S, Nagasaki Y, Arimizu Y, Neurological disorders identified during treatment of a SARS-CoV-2 infection: Intern Med, 2020; 59(17); 2187-89
9.. Cea G, Romero C, Aguilar S, Salinas R, Guillain-Barré syndrome in patients with SARS-CoV-2 infection. Report of three cases: Rev Med Chile, 2021; 149(12); 1812-16
10.. Rajdev K, Victor N, Buckholtz ES, A case of Guillain-Barré syndrome associated with COVID-19: J Investig Med High Impact Case Rep, 2020; 8 2324709620961198
11.. Rane RP, Jain A, Hussain KM, A rare case of Guillain-Barré syndrome associated with SARS-CoV-2 infection requiring mechanical ventilation.: Cureus., 2022; 14(6); e25810
12.. Yiu AC, Hussain A, Okonkwo UA, Guillain-Barré syndrome associated with COVID-19 pneumonia – the first documented case in a U.S. Military Intensive Care Unit.: Military Medicine, 2023; 188(3–4); e852-e56
13.. Diaz P, Leveque M, Hautecloque G, The challenge of diagnosing Guillain-Barré syndrome in patients with COVID-19 in the intensive care unit: J Neuroimmunol, 2022; 366; 577842
14.. Labbad I, Shammas I, Abbas A, Guillan-Barré syndrome during COVID-19 pandemic: A case series from Syria: Ann Med Surgery (Lond), 2023; 85(6); 3166-70
15.. Sidhom F, Sandhu H, Guillain-Barré syndrome in a patient with COVID-19 infection: Cureus, 2021; 13(8); e17052
16.. Okhovat AA, Ansari B, Hemasian H, Guillain-Barré syndrome in patients with coronavirus disease-2019: Report of six cases and review of literature: Curr J Neurol, 2020; 19(3); 122-30
17.. Webb S, Wallace VC, Martin-Lopez D, Yogarajah M, Guillain-Barré syndrome following COVID-19: A newly emerging post-infectious complication: BMJ Case Rep, 2020; 13(6); e236182
Figures
Tables
In Press
Case report
Dual Hepatic Injury from Refeeding Syndrome and Starvation in a Malnourished Woman After Bariatric Surgery:...Am J Case Rep In Press; DOI: 10.12659/AJCR.944088
Case report
Rapid Healing of Palatal Necrosis with Active Oxygen Gel: A Case Report and Management StrategyAm J Case Rep In Press; DOI: 10.12659/AJCR.945135
Case report
Late-Onset Hemophagocytic Lymphohistiocytosis in a Lung Transplant Patient: A Case of T-Cell Post-Transplan...Am J Case Rep In Press; DOI: 10.12659/AJCR.944761
Case report
Dantrolene for Control of Refractory Shivering in Severe Traumatic Brain Injury: A Case StudyAm J Case Rep In Press; DOI: 10.12659/AJCR.944980
Most Viewed Current Articles
21 Jun 2024 : Case report 58,722
Intracranial Parasitic Fetus in a Living Infant: A Case Study with Surgical Intervention and Prognosis Anal...DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report 42,753
Neurocysticercosis Presenting as Migraine in the United StatesDOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133
10 Jan 2022 : Case report 32,479
A Report on the First 7 Sequential Patients Treated Within the C-Reactive Protein Apheresis in COVID (CACOV...DOI :10.12659/AJCR.935263
Am J Case Rep 2022; 23:e935263
23 Feb 2022 : Case report 20,016
Penile Necrosis Associated with Local Intravenous Injection of CocaineDOI :10.12659/AJCR.935250
Am J Case Rep 2022; 23:e935250